Pfizer scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Pfizer increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Pfizer forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Pfizer has used its political contributions to advance ideological causes, groups, and policies. Pfizer is a platinum partner of the Human Rights Campaign (HRC), funds Planned Parenthood, and multiple LGBTQ organizations. Pfizer supports the Equality Act and its leadership has been outspoken on topics such as transgender activism. Pfizer's CEO is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism. Pfizer partially funds HRC's Healthcare Equality Index. The company opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. Pfizer signed the Health Sector Climate Pledge, committing itself to achieve net zero emissions by 2050. The company is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. For these reasons, Pfizer receives a High Risk rating.